Major advances have been made in precision medicine of breast cancer patients with a
series of molecular targeted therapies now in clinical use or in late clinical development …

ObjectivesRecent studies on the quality of life in women with breast cancer show a high
prevalence of signs and symptoms that should be the focus of palliative care (PC), leading …

Introduction Cyclin-dependent kinase (CDK) 4/6 inhibitor is a first-line therapy for metastatic
ER+/HER2-breast cancer. However, there are limited data on safety of combined …

The objective of the present study was to assess the outcomes and toxicity of patients
treated with concurrent administration of CDK4/6 inhibitors (CDK4/6i) and locoregional …

Purpose Our purpose was to investigate radiation therapy (RT) toxicity when given with
cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) compared with RT alone. Methods and …

Simple Summary CDK4/6 inhibitors target cell proliferation resulting in toxicity, mainly bone
marrow suppression manifesting as neutropenia. Radiation therapy (RT), widely used in …

Abstract Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy
(ET) are now a backbone of treatment for hormone receptor-positive/human epidermal …

Abstract Purpose Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) currently represent the
standard of care for the initial treatment of patients with metastatic hormone receptor …

Purpose Many patients with metastatic cancer live years beyond diagnosis, and there
remains a need to improve the therapeutic ratio of metastasis-directed radiation for these …

Background There is a lack of data on combined radiotherapy (RT) and cyclin-dependent
kinase 4 and 6 inhibitor (CDK4/6i) risk factors and toxicity. This study aimed to assess the …